• Edwards Lifesciences recently raised its full-year 2026 sales and TAVR growth guidance and completed the acquisition of Autus Valve Technologies, further expanding its structural heart portfolio beyond TAVR.
• This combination of higher guidance and broader coverage across aortic, mitral, and tricuspid therapies underscores how Edwards is deepening its role in treating complex structural heart disease.
• Next, we’ll examine how the upgraded sales outlook, particularly for TAVR, may reshape Edwards Lifesciences’ existing investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Edwards Lifesciences Investment Narrative Recap

To own Edwards Lifesciences, you need to believe in long term demand for less invasive structural heart therapies and Edwards’ ability to keep innovating in TAVR, mitral, and tricuspid valves despite competition and regulatory complexity. The upgraded 2026 sales and TAVR guidance, alongside the Autus Valve deal, reinforces the near term growth story, while tariffs, rising R&D spend, and pressure on international TAVR volumes remain key risks to watch.

Among the recent announcements, Edwards’ raised full year 2026 sales outlook to US$6.5 billion to US$6.9 billion stands out as most directly tied to this news, as it folds higher TAVR expectations and portfolio expansion into a clearer revenue framework. That updated guidance now sits alongside ongoing investments in tricuspid (EVOQUE) and mitral (Sapien M3) therapies, which many investors see as important catalysts if adoption tracks regulatory and policy progress.

But against that stronger guidance, investors should also be aware that rising tariffs and higher operating expenses could...

Edwards Lifesciences' narrative projects $8.3 billion revenue and $2.2 billion earnings by 2029. This requires 9.6% yearly revenue growth and an earnings increase of about $1.1 billion from $1.1 billion today.

Uncover how Edwards Lifesciences' forecasts yield a $96.92 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community cluster between US$91.48 and US$96.92, showing how tightly some investors bracket Edwards’ prospects. Set against this, the upgraded 2026 sales and TAVR outlook highlights how differing views on growth resilience can shape very different expectations for the company’s performance over time.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 13% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.